title: Remifentanil versus remifentanil with paracervical block on plasma remifentanil concentrations and pulmonary function tests for transvaginal ultrasound-guided oocyte retrieval.
abstract: OBJECTIVE
  The aim of this study is to compare plasma remifentanil concentrations and pulmonary function tests in subjects receiving remifentanil infusion (RI) versus RI with paracervical block (PCB) during transvaginal ultrasound-guided oocyte retrieval (TUGOR).
  
  
  METHODS
  Prospective, randomized.
  
  
  METHODS
  Assisted Conception Unit.
  
  
  METHODS
  Forty American Society ofAnesthesiologists I subjects requiring TUGOR.
  
  
  METHODS
  After ovarian hyperstimulation, subjects were randomly allocated into two groups to receive either RI (Group RI, n = 20) or RI with PCB (Group RI + PCB, n = 20).
  
  
  METHODS
  Heart rate (HR), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2), end tidal carbon dioxide (ETCO2) tension, forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), and amount of remifentanil used were collected. Plasma remifentanil concentrations were calculated with STANPUMP software.
  
  
  RESULTS
  HR, MAP, ETCO2, SpO2, FEV1, and FVC did not differ between the groups. Total amount of remifentanil used were 486 +/- 1.81 microg and 321 +/- 0.87 microg in groups RI and RI + PCB, respectively, (p < 0.05). In Group RI, plasma remifentanil concentrations were 4.7 ng mL(-1) and 4.2 ng mL(-1) during the second transvaginal puncture, and at the end of TUGOR, respectively, whereas corresponding plasma remifentanil concentrations were 3.1 ng mL(-1) and 2.6 ng mL(-1) in Group RI + PCB (p < 0.05).
  
  
  CONCLUSIONS
  Both anesthesia regimens provided satisfactory analgesia without affecting FEV1 and FVC, but significantly higher plasma remifentanil concentrations were calculated when only RI was used as an anesthetic technique.
authors.affiliation: Department of Anesthesiology, Faculty of Medicine, Gazi University, Ankara, Turkey.
authors.forename: Berrin
authors.initials: B
authors.lastname: Gunaydin
authors.forename: I Kivilcim
authors.initials: IK
authors.lastname: Ozulgen
authors.forename: Ertan
authors.initials: E
authors.lastname: Ozturk
authors.forename: Zeki T
authors.initials: ZT
authors.lastname: Tekgul
authors.forename: Kadir
authors.initials: K
authors.lastname: Kaya
mesh_terms: D000328:Adult; D018686:Anesthetics, Intravenous / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002245:Carbon Dioxide / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D005541:Forced Expiratory Volume / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D009407:Nerve Block; D054315:Oocyte Retrieval; D010101:Oxygen Consumption / Q000187:drug effects; D017060:Patient Satisfaction; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood; D000077208:Remifentanil; D012129:Respiratory Function Tests; D014465:Ultrasonics; D014797:Vital Capacity / Q000187:drug effects
chemical_list: D018686:Anesthetics, Intravenous; D010880:Piperidines; D002245:Carbon Dioxide; D000077208:Remifentanil